Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2005
11/17/2005WO1997049725A9 Modified factor viii
11/17/2005US20050257276 FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
11/17/2005US20050256304 Modified factor VIII
11/17/2005US20050256303 Having antibacterial activity, antioxidative effect, inflammation inhibitory effect, in vivo substance transporting action, and enzymatic activity, used as a drug administration carrier
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256301 Pain, stroke, traumatic brain injury, blocking a voltage-sensitive calcium channel, blocking the nicotinic acetylcholine receptor; synthetic, has no free N- or C-terminus, cysteine residues bonded to form a disulfide bond
11/17/2005US20050256298 Method for preparing free flow resin
11/17/2005US20050256134 Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
11/17/2005US20050256104 Protease inhibitors
11/17/2005US20050256075 Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
11/17/2005US20050256074 Methods and compositions for regulating lymphocyte activity
11/17/2005US20050256071 Inhibitor nucleic acids
11/17/2005US20050256067 Method of preparing a treatment product, treatment product and a plasmid construct
11/17/2005US20050256059 administering D-mannose for producing neurosalutary effect in a patient useful in treatment of neurological disorders, including retinal and optic nerve damage
11/17/2005US20050256058 Propenoyl hydrazides
11/17/2005US20050256057 Proline-specific endoprotease and tripeptidase digested polypeptide mixture comprising tripeptides for use in pharmaceuticals and nutraceuticals
11/17/2005US20050256056 Peptide inhibitors of HIV
11/17/2005US20050256055 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
11/17/2005US20050256054 Drug therapy for celiac sprue
11/17/2005US20050256053 Combined use of a GLP-1 compound and another drug for treating dyslipidemia
11/17/2005US20050256052 Isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle and nerve tissue formation; binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256050 Vascular endothelial growth factor 2
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050256047 Method for fostering bone formation and preservation
11/17/2005US20050256046 obtaining a sequence-defined molecular weight markers that provide an accurate and robust calibration set for determinations of molecular weight of production batches; subjecting the molecular weight markers to column chromatography to establish a relationship between retention time and molecular weight
11/17/2005US20050256045 Apparatus and method for transdermal delivery of parathyroid hormone agents
11/17/2005US20050256044 Gastrointestinal proliferative factor and uses thereof
11/17/2005US20050256043 chemokines; open reading frames; long terminal repeats; site directed mutagenesis; antibodies
11/17/2005US20050256042 Methods of preventing and treating alimentary mucositis
11/17/2005US20050256041 polypeptides, polynucleotides encoding the polypeptides and antibodies, for detecting ligands, as well as agonists and antagonists, modulation of tumor growth, metastasis and immunology
11/17/2005US20050256040 Artificially designed pore-forming proteins with anti-tumor effects
11/17/2005US20050256039 Novel fibroblast growth factors and methods of use thereof
11/17/2005US20050256038 Stable pharmaceutical compsition containing factor VIII
11/17/2005US20050256037 Antibacterial amide macrocyles
11/17/2005US20050256036 Gastrointestinal proliferative factor and uses thereof
11/17/2005US20050256035 Ctp-extended erythropoietin
11/17/2005US20050256034 Dioxolane analogs for improved inter-cellular delivery
11/17/2005US20050256032 Polyoxyalkylene compound and method for making
11/17/2005US20050256031 Composition for relieving discomfort
11/17/2005US20050256030 Heterocyclic self-immolative linkers and conjugates
11/17/2005US20050256028 Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
11/17/2005US20050255573 An in vitro method of maintaining a mouse or human pluripotent cell in a pluripotent state by increasing expression of a gene that encodes a factor which acts intracellularly and maintainspluripotency, where the factor is a polypeptide of the sequence of SEQ ID NO: 4; cultures
11/17/2005US20050255560 Ztnf11, a tumor necrosis factor
11/17/2005US20050255558 Signal sequence polypeptides for diagnosis, prevention and treatment of metabolic disorders
11/17/2005US20050255553 Mage C2 antigenic peptides and uses thereof
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255543 Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration
11/17/2005US20050255537 Method for monitoring treatment with a parathyroid hormone
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255521 59079 and 12599, protein kinase family members and uses therefor
11/17/2005US20050255519 Reagents and methods useful for detecting diseases of the prostate
11/17/2005US20050255518 Methods and compositions for the treatment and diagnosis of pain disorders using 46566
11/17/2005US20050255511 Fra-1 expression in brain cancer
11/17/2005US20050255510 Fra-1 expression in brain cancer
11/17/2005US20050255493 Molecular targeting of the IGF-1 receptor
11/17/2005US20050255490 Novel G protein-coupled receptors
11/17/2005US20050255460 Detecting presence of human papillomavirus E6 proteins using polypeptide comprising modular protein domains (PDZ); screening for cell proliferative disorders
11/17/2005US20050255454 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy
11/17/2005US20050255228 Process for controlling protein to salt ratio in animal muscle protein composition and protein composition
11/17/2005US20050255182 Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
11/17/2005US20050255173 Anticancer composition
11/17/2005US20050255167 Medicinal Agent for Preventing and Treating Endocrine System Disturbances
11/17/2005US20050255163 Co-grinding process for the preparation of a ternary composition
11/17/2005US20050255162 Hydrophobic biomolecular structure
11/17/2005US20050255152 System for enhanced targeted delivery
11/17/2005US20050255141 Biological scaffolds comprising bone morphogenic protein for use in induction endochondral bone growth and treatment of bone disorders; tissue repair
11/17/2005US20050255138 Active agent transport systems
11/17/2005US20050255128 Quorum sensing and biofilm formation
11/17/2005US20050255122 particularly, preventing or ameliorating the neuropathology of Alzheimer's disease, by administering an A beta peptide having a specific amino acid sequence and an adjuvant that enhances the immune response
11/17/2005US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
11/17/2005US20050255112 Compositions and methods for preventing erythropoietin-associated hypertension
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005US20050255108 For improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size in absence of removal of the arterial obstruction; administering anti-CD18 antibody
11/17/2005US20050255107 Anti-angiogenic proteins and fragments and methods of use thereof
11/17/2005US20050255104 administering antibodies or antigen-binding fragments which are specific for human tumor necrosis factor- alpha (TNF alpha), used for in vivo medical diagnosis and therapy; immunoassay and immunotherapy
11/17/2005US20050255100 Isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5; tumor necrosis factor blocking agent; cyclosporine immunosuppressant; antibiotic; anti-inflammatory; graft versus host disease, viral infection, cancer, leukemia, immunodeficiency, autoimmune disorder
11/17/2005US20050255099 Antigenic fusion protein carrying Galalpha 1,3Gal epitopes
11/17/2005US20050255097 Modified venom and venom components as anti-retroviral agents
11/17/2005US20050255096 Combination treatment for acute myocardial infarction
11/17/2005US20050255095 Destruction of prions using vibrolysin or variants thereof
11/17/2005US20050255094 Mitogen-activated protein kinase kinase MEK6 and methods of use therefor
11/17/2005US20050255093 treating nervous system disorders induced by stroke or injury, injured by trauma to reduce oxidative stress, administering a conjugate of antioxidant enzyme and a clostridial neurotoxin cell binding domain, and a clostridial neurotoxin translocation domain; tissue-targeted therapy
11/17/2005US20050255088 Administering mutant Salmonella sp. for therapy of solid tumor cancer, disrupted msbB gene and is capable of targeting a solid tumor cancer
11/17/2005US20050255086 Adeno-associated viral vector comprising short interfering RNA for use in the treatment of nervous system disorders; tissue engineering and gene therapy; tissue targeted therapy
11/17/2005US20050255085 Prevention of recurrence and metastasis of cancer
11/17/2005US20050255083 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2005US20050255071 Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
11/17/2005US20050255051 Formulation for inhalation
11/17/2005US20050255039 Gel injection treatment of breast, fibroids & endometrial ablation
11/17/2005US20050255038 Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005DE102004019736A1 Use of a calcitonin gene related peptide antagonist and a serotonin reuptake inhibitor to treat headaches, migraine and cluster headaches
11/17/2005CA2566400A1 An agent comprising fgf2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease
11/17/2005CA2565731A1 Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
11/17/2005CA2565701A1 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
11/17/2005CA2565457A1 Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
11/17/2005CA2565387A1 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
11/17/2005CA2565250A1 Cysteamines for treating complications of hypercholesterolemia and diabetes
11/17/2005CA2565227A1 Human complement c3 derivates with cobra venom factor-like function
1 ... 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 ... 3163